A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
This study is ongoing, but not recruiting participants.
Study NCT01285323
Information provided by Teva Pharmaceutical Industries
First Received on January 25, 2011.
Last Updated on March 19, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
